{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:22:32Z","timestamp":1792452152498,"version":"4.5.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"am","delay-in-days":254,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007130","name":"University of Texas System","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["ZIAMH002857"],"award-info":[{"award-number":["ZIAMH002857"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jad.2025.120016","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T23:10:27Z","timestamp":1754521827000},"page":"120016","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Blood-based biomarkers in ketamine treatment: A blueprint for translational drug development in mood disorders"],"prefix":"10.1016","volume":"390","author":[{"given":"Alan C.","family":"Courtes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory H.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioline D.","family":"Henter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lokesh","family":"Shahani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel R.","family":"Fries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario F.","family":"Juruena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jair C.","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Carlos A.","family":"Zarate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Machado-Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2025.120016_bb0005","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/s41386-020-0644-9","article-title":"Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin","volume":"45","author":"Abdallah","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2025.120016_bb0010","doi-asserted-by":"crossref","DOI":"10.1177\/24705470211014210","article-title":"Biomarkers of ketamine's antidepressant effect: a clinical review of genetics, functional connectivity, and neurophysiology","volume":"5","author":"Alario","year":"2021","journal-title":"Chronic Stress"},{"key":"10.1016\/j.jad.2025.120016_bb0015","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jad.2015.06.033","article-title":"Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: a comparison of ketamine and ECT","volume":"186","author":"Allen","year":"2015","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.120016_bb0020","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41577-019-0131-x","article-title":"Cytokine-mediated communications: a quantitative appraisal of immune complexity","volume":"19","author":"Altan-Bonnet","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jad.2025.120016_bb0025","first-page":"961","article-title":"Ketamine versus ECT for nonpsychotic treatment-resistant major depression","volume":"389","author":"Anand","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2025.120016_bb0030","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature10130","article-title":"NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses","volume":"475","author":"Autry","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jad.2025.120016_bb0035","doi-asserted-by":"crossref","first-page":"S295","DOI":"10.1016\/j.biopsych.2021.02.734","article-title":"Ketamine and rapamycin in combination is effective for diverse treatment resistant disease","volume":"89","author":"Berner","year":"2021","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2025.120016_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059498","article-title":"Performance of multiplex cytokine assays in serum and saliva among community-dwelling postmenopausal women","volume":"8","author":"Browne","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jad.2025.120016_bb0045","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.adh1178","article-title":"ALOX5 drives the pyroptosis of CD4+ T cells and tissue inflammation in rheumatoid arthritis","volume":"17","author":"Cai","year":"2024","journal-title":"Sci. Signal."},{"key":"10.1016\/j.jad.2025.120016_bb0050","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1109\/TBME.2018.2877651","article-title":"Identifying ketamine responses in treatment-resistant depression using a wearable forehead EEG","volume":"66","author":"Cao","year":"2019","journal-title":"IEEE Trans. Biomed. Eng."},{"key":"10.1016\/j.jad.2025.120016_bb0055","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.psychres.2018.08.078","article-title":"Rapid inflammation modulation and antidepressant efficacy of a low-dose ketamine infusion in treatment-resistant depression: a randomized, double-blind control study","volume":"269","author":"Chen","year":"2018","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2025.120016_bb0060","article-title":"Serine supports IL-1\u03b2 production in macrophages through mTOR signaling","volume":"11","author":"Chen","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jad.2025.120016_bb0065","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/JCP.0000000000001149","article-title":"Metabolic syndrome rather than body mass index is associated with treatment response to ketamine infusions","volume":"40","author":"Dale","year":"2020","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2025.120016_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2021.110507","article-title":"Electrophysiological correlates and predictors of the antidepressant response to repeated ketamine infusions in treatment-resistant depression","volume":"115","author":"De La Salle","year":"2022","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2025.120016_bb0075","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/15622975.2022.2097739","article-title":"Changes in adipokine concentrations in antidepressant-resistant bipolar depression after ketamine infusion and electroconvulsive therapy","volume":"24","author":"Dmitrzak-Weglarz","year":"2023","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2025.120016_bb0080","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jalz.2015.08.003","article-title":"Performance and complications of lumbar puncture in memory clinics: results of the multicenter lumbar puncture feasibility study","volume":"12","author":"Duits","year":"2016","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jad.2025.120016_bb0085","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41386-020-0663-6","article-title":"Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression","volume":"45","author":"Farmer","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2025.120016_bb0090","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1146\/annurev.immunol.14.1.397","article-title":"Role of cytokines in rheumatoid arthritis","volume":"14","author":"Feldmann","year":"1996","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jad.2025.120016_bb0095","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S2215-0366(21)00395-3","article-title":"Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study 2019","volume":"9","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jad.2025.120016_bb0100","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jpsychires.2019.08.005","article-title":"Ketamine metabolite pilot study in a suicidal depression trial","volume":"117","author":"Grunebaum","year":"2019","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2025.120016_bb0105","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1017\/S1461145713001119","article-title":"Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression","volume":"17","author":"Haile","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2025.120016_bb0110","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3988\/jcn.2021.17.4.503","article-title":"How inflammation affects the brain in depression: a review of functional and structural MRI studies","volume":"17","author":"Han","year":"2021","journal-title":"J. Clin. Neurol."},{"key":"10.1016\/j.jad.2025.120016_bb0115","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1136\/jnnp-2022-329530","article-title":"Clinical utility of cerebrospinal fluid biomarkers in the evaluation of cognitive impairment: a systematic review and meta-analysis","volume":"94","author":"Hazan","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jad.2025.120016_bb0120","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jalz.2013.01.013","article-title":"The future of blood-based biomarkers for Alzheimer\u2019s disease","volume":"10","author":"Henriksen","year":"2014","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.jad.2025.120016_bb0125","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1007\/s00213-016-4256-3","article-title":"Rapamycin blocks the antidepressant effect of ketamine in task-dependent manner","volume":"233","author":"Holubova","year":"2016","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jad.2025.120016_bb0130","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jad.2017.09.035","article-title":"Cerebrospinal fluid D-serine concentrations in major depressive disorder negatively correlate with depression severity","volume":"226","author":"Ishiwata","year":"2018","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.120016_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103518","article-title":"Inflammation, stress and depression: an exploration of ketamine\u2019s therapeutic profile","volume":"28","author":"Johnston","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jad.2025.120016_bb0140","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1038\/mp.2017.109","article-title":"Acute ketamine administration corrects abnormal inflammatory bone markers in major depressive disorder","volume":"23","author":"Kadriu","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2025.120016_bb0145","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19ac13138","article-title":"Not so fast: recent successes and failures in treating depression","volume":"81","author":"Kadriu","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2025.120016_bb0150","first-page":"220","article-title":"Efficacy of different doses of ketamine as a bolus in major depressive disorder","volume":"9","author":"Kheirkhah","year":"2018","journal-title":"Caspian J. Intern. Med."},{"key":"10.1016\/j.jad.2025.120016_bb0155","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1017\/S0033291716000064","article-title":"Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories","volume":"46","author":"Kishimoto","year":"2016","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jad.2025.120016_bb0160","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1177\/02698811211026426","article-title":"Ketamine\u2019s effect on inflammation and kynurenine pathway in depression: a systematic review","volume":"35","author":"Kopra","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2025.120016_bb0165","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.neuron.2019.02.005","article-title":"Ketamine: a paradigm shift for depression research and treatment","volume":"101","author":"Krystal","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.jad.2025.120016_bb0170","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41386-023-01629-w","article-title":"Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms","volume":"49","author":"Krystal","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2025.120016_bb0175","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jad.2022.06.043","article-title":"Association between peripheral inflammation and free-water imaging in major depressive disorder before and after ketamine treatment - a pilot study","volume":"314","author":"Langhein","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.120016_bb0180","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.jad.2025.120016_bb0185","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1215861","article-title":"Aminooxy acetic acid suppresses Th17-mediated psoriasis-like skin inflammation by inhibiting serine metabolism","volume":"14","author":"Lee","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jad.2025.120016_bb0190","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1190287","article-title":"mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"Li","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.jad.2025.120016_bb0195","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.biopsych.2010.12.015","article-title":"Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure","volume":"69","author":"Li","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2025.120016_bb0200","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/s41386-021-01242-9","article-title":"Identification of an optimal dose of intravenous ketamine for late-life treatment-resistant depression: a Bayesian adaptive randomization trial","volume":"47","author":"Lijffijt","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2025.120016_bb0205","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41380-019-0474-5","article-title":"Peripheral cytokine levels and response to antidepressant treatment in depression: a systematic review and meta-analysis","volume":"25","author":"Liu","year":"2020","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2025.120016_bb0210","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.4088\/JCP.08m04659","article-title":"Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist","volume":"70","author":"Machado-Vieira","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2025.120016_bb0215","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/mp.2016.36","article-title":"The role of adipokines in the rapid antidepressant effects of ketamine","volume":"22","author":"Machado-Vieira","year":"2017","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2025.120016_bb0220","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1038\/s41380-022-01652-1","article-title":"Blood-based biomarkers of antidepressant response to ketamine and esketamine: a systematic review and meta-analysis","volume":"27","author":"Medeiros","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2025.120016_bb0225","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S2215-0366(23)00183-9","article-title":"Brain-based correlates of antidepressant response to ketamine: a comprehensive systematic review of neuroimaging studies","volume":"10","author":"Medeiros","year":"2023","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jad.2025.120016_bb0230","first-page":"211","article-title":"Precision pharmacotherapy: psychiatry's future direction in preventing, diagnosing, and treating mental disorders","volume":"11","author":"Menke","year":"2018","journal-title":"Pharmacogenomics Pers. Med."},{"key":"10.1016\/j.jad.2025.120016_bb0235","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jad.2022.12.021","article-title":"Biomarkers of ketamine\u2019s antidepressant effect: an umbrella review","volume":"323","author":"Meshkat","year":"2023","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.120016_bb0240","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.13211","article-title":"Assessment of relationship of ketamine dose with magnetic resonance spectroscopy of Glx and GABA responses in adults with major depression: a randomized clinical trial","volume":"3","author":"Milak","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jad.2025.120016_bb0245","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-014-3669-0","article-title":"D-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with treatment-resistant depression","volume":"232","author":"Moaddel","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jad.2025.120016_bb0250","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41398-022-01941-x","article-title":"Comparative metabolomic analysis in plasma and cerebrospinal fluid of humans and in plasma and brain of mice following antidepressant-dose ketamine administration","volume":"12","author":"Moaddel","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jad.2025.120016_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.108527","article-title":"Cerebrospinal fluid exploratory proteomics and ketamine metabolite pharmacokinetics in human volunteers after ketamine infusion","volume":"26","author":"Moaddel","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.jad.2025.120016_bb0260","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1001\/jamapsychiatry.2022.0645","article-title":"Cerebrospinal fluid biomarkers in patients with unipolar depression compared with healthy control individuals: a systematic review and meta-analysis","volume":"79","author":"Mousten","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2025.120016_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102127","article-title":"Ketamine for the treatment of major depression: a systematic review and meta-analysis","volume":"62","author":"Nikolin","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.jad.2025.120016_bb0270","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/s41380-018-0028-2","article-title":"Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects","volume":"24","author":"Nugent","year":"2019","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2025.120016_bb0275","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.pscychresns.2018.09.001","article-title":"Synaptic potentiation and rapid antidepressant response to ketamine in treatment-resistant major depression: a replication study","volume":"283","author":"Nugent","year":"2019","journal-title":"Psychiatry Res. Neuroimaging"},{"key":"10.1016\/j.jad.2025.120016_bb0280","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2020.00519","article-title":"The effect of ketamine on electrophysiological connectivity in major depressive disorder","volume":"11","author":"Nugent","year":"2020","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.jad.2025.120016_bb0285","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jpsychires.2018.08.028","article-title":"Cerebrospinal fluid monoamine metabolite concentrations in depressive disorder: a meta-analysis of historic evidence","volume":"105","author":"Ogawa","year":"2018","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2025.120016_bb0290","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.65","article-title":"Major depressive disorder","volume":"2","author":"Otte","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.jad.2025.120016_bb0295","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jad.2018.07.031","article-title":"Poor evidence for putative abnormalities in cerebrospinal fluid neurotransmitters in patients with depression versus healthy non-psychiatric individuals: a systematic review and meta-analyses of 23 studies","volume":"240","author":"Pech","year":"2018","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.120016_bb0300","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1415505","article-title":"Baseline monocyte count predicts symptom improvement during intravenous ketamine therapy in treatment-resistant depression: a single-arm open-label observational study","volume":"15","author":"Pedraz-Petrozzi","year":"2024","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.jad.2025.120016_bb0305","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s00702-019-02084-y","article-title":"Animal models of major depression: drawbacks and challenges","volume":"126","author":"Planchez","year":"2019","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.jad.2025.120016_bb0310","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.8236.1","article-title":"In search of the mechanisms of ketamine's antidepressant effects: how robust is the evidence behind the mTOR activation hypothesis","volume":"5","author":"Popp","year":"2016","journal-title":"F1000Research"},{"key":"10.1016\/j.jad.2025.120016_bb0315","doi-asserted-by":"crossref","first-page":"5096","DOI":"10.1038\/s41380-022-01757-7","article-title":"International pooled patient-level meta-analysis of ketamine infusion for depression: in search of clinical moderators","volume":"27","author":"Price","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2025.120016_bb0320","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/cpt.3391","article-title":"A phase 1 assessment of the safety, tolerability, pharmacokinetics and pharmacodynamics of (2R,6R)-hydroxynorketamine in healthy volunteers","volume":"116","author":"Raja","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jad.2025.120016_bb0325","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph15040771","article-title":"Predictors of response to ketamine in treatment resistant major depressive disorder and bipolar disorder","volume":"15","author":"Rong","year":"2018","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.jad.2025.120016_bb0330","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00406-022-01460-2","article-title":"The effects of ketamine and classic hallucinogens on neurotrophic and inflammatory markers in unipolar treatment-resistant depression: a systematic review of clinical trials","volume":"273","author":"Rossi","year":"2023","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.jad.2025.120016_bb0335","doi-asserted-by":"crossref","first-page":"e894","DOI":"10.1038\/tp.2016.145","article-title":"Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants","volume":"6","author":"Rotroff","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jad.2025.120016_bb0340","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41398-020-01122-8","article-title":"Studying pre-treatment and ketamine-induced changes in white matter microstructure in the context of ketamine's antidepressant effects","volume":"10","author":"Snyder","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jad.2025.120016_bb0345","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.2147\/NDT.S114542","article-title":"Biomarkers for depression: recent insights, current challenges and future prospects","volume":"13","author":"Strawbridge","year":"2017","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.jad.2025.120016_bb0350","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jad.2010.11.019","article-title":"The association between depressive and anxiety symptoms and bone mineral density in the general population: the HUNT Study","volume":"131","author":"Williams","year":"2011","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.120016_bb0355","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyv124","article-title":"Effects of low-dose and very low-dose ketamine among patients with major depression: a systematic review and meta-analysis","volume":"19","author":"Xu","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2025.120016_bb0360","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.biopsych.2017.05.016","article-title":"Mechanistic target of rapamycin\u2013independent antidepressant effects of (R)-ketamine in a social defeat stress model","volume":"83","author":"Yang","year":"2018","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2025.120016_bb0365","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.biopsych.2014.06.021","article-title":"Serum interleukin-6 is a predictive biomarker for ketamine's antidepressant effect in treatment-resistant patients with major depression","volume":"77","author":"Yang","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2025.120016_bb0370","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/mp.2017.255","article-title":"Mechanisms of ketamine action as an antidepressant","volume":"23","author":"Zanos","year":"2018","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2025.120016_bb0375","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jad.2025.120016_bb0380","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.117.015198","article-title":"Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms","volume":"70","author":"Zanos","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.jad.2025.120016_bb0385","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1523\/JNEUROSCI.1316-22.2022","article-title":"NMDA receptor activation-dependent antidepressant-relevant behavioral and synaptic actions of ketamine","volume":"43","author":"Zanos","year":"2023","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jad.2025.120016_bb0390","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.biopsych.2012.03.004","article-title":"Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression","volume":"72","author":"Zarate","year":"2012","journal-title":"Biol. Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725014582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725014582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T14:09:58Z","timestamp":1779718198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032725014582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":78,"alternative-id":["S0165032725014582"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2025.120016","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blood-based biomarkers in ketamine treatment: A blueprint for translational drug development in mood disorders","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2025.120016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"120016"}}